Melanotan II

Melanotan II is a synthetic cyclic heptapeptide that activates melanocortin receptors, particularly MC1R (responsible for skin pigmentation), MC3R, and MC4R (responsible for sexual arousal and appetite suppression). It produces darkening of the skin and pronounced sexual side effects through central nervous system activation. It was developed at the University of Arizona by Victor Hruby and colleagues in the 1980s based on the structure of alpha-melanocyte stimulating hormone (α-MSH). It has no FDA approval, no EMA approval, and no marketing authorization in any country.

The molecule's full structural designation is Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH₂ with a cyclic disulfide bond between the Asp and Lys side chains. The non-selective melanocortin receptor activation is responsible for its complex effects profile. MC1R activation stimulates melanocytes to produce melanin, darkening the skin. MC3R and MC4R activation drive central sexual arousal and appetite suppression, which is why early Phase 1 subjects in tanning trials reported intense sexual side effects. Researchers separated these effects in a later modification, producing bremelanotide (PT-141) with selective MC4R activity. PT-141 received FDA approval in 2019 for hypoactive sexual desire disorder. Melanotan II did not.

The compound has not been developed pharmaceutically by any company. There is no Phase 2 or Phase 3 program. All current "Melanotan II" supply comes from research-chemical synthesis labs sold through online vendors with "for laboratory use only" labeling that the resale ecosystem routinely ignores.

The Evidence Base: What Limited Trials Exist

The University of Arizona group conducted small Phase 1 trials of Melanotan II in the late 1980s and early 1990s. Published reports documented effective pigmentation with subcutaneous dosing in fair-skinned subjects. Side effects included nausea, facial flushing, and intense sexual arousal. The sexual side effects were sufficiently pronounced to derail the development program for the original tanning indication, leading to the structural modification that produced bremelanotide.

A small open-label trial of Melanotan II in patients with erythropoietic protoporphyria (a photosensitivity disorder) was conducted with limited follow-up. The compound has not been further developed for this indication despite mechanistic relevance.

Beyond these early Arizona trials, the published evidence base for Melanotan II is dominated by adverse-event case reports. PubMed searches return more clinical literature on side effects (melanoma, dysplastic nevi, priapism, pancreatitis, hyperpigmentation) than on efficacy. This is unusual for a peptide and reflects the absence of formal pharmaceutical development combined with the public-health interest generated by the unregulated market.

Melanotan II is a non-selective melanocortin receptor agonist. The receptor activity profile across the melanocortin system explains the compound's clinical pattern.

MC1R activation in melanocytes triggers melanogenesis. Melanocytes increase production of eumelanin (the dark pigment) and migrate small amounts toward the skin surface. The result is increased skin pigmentation that develops over days to weeks of dosing. The tanning effect is generally uniform but can be patchy in patients with existing dyschromia or sun damage.

MC4R activation in the hypothalamus drives the sexual side effects. The same receptor that PT-141 targets for HSDD treatment is activated by Melanotan II, but without the selective tuning that allows PT-141 to produce sexual response without other effects. MC4R activation also reduces appetite, which is why some users report unintended weight loss during dosing.

MC3R activation contributes to autonomic effects including blood pressure changes and possible cardiovascular signals.

Off-target effects include nausea (the most common adverse event), facial flushing, transient blood pressure increase, and altered libido patterns that can persist for hours after dosing.

The pharmacokinetic profile is approximate. Subcutaneous injection produces peak plasma levels within an hour. The half-life is short (around 30 to 60 minutes), but the pigmentation effects persist far longer because melanin production cascades downstream of the peptide's direct receptor activity.

Regulatory status

Melanotan II has no FDA approval for any indication in any country. There is no EMA approval, no MHRA approval, no Health Canada authorization, and no marketing authorization in any major regulatory jurisdiction.

The compound was added to the FDA Category 2 bulks list under Section 503A in September 2023 alongside BPC-157, CJC-1295, and others. Category 2 status prohibits 503A and 503B compounding pharmacies from preparing the compound. Melanotan II is one of the substances scheduled for reconsideration at the PCAC meeting on July 23 and 24, 2026, though a Category 1 recommendation is unlikely given the documented adverse-event profile.

In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) has issued specific warnings about Melanotan II since 2008, citing the safety signal and unregulated production. The MHRA has prosecuted vendors selling the compound. Similar warnings have been issued by health authorities in Ireland, Australia, and several EU member states.

Melanotan II is not specifically on the WADA Prohibited List but would fall under section S0 (Non-Approved Substances) for athletes, since it has no marketing authorization anywhere in the world. The compound is also not relevant to typical sport performance.

The compound continues to be sold through online "research chemical" vendors with labeling that the resale ecosystem ignores. Quality control on these products is variable. Several independent analyses have identified mislabeled, underpotent, and contaminated products under the "Melanotan II" name.

Dosing protocols and literature-reported ranges are documented in the approved label or trial publications referenced above.

The Melanotan II adverse-event profile is the most significant clinical issue with the compound and deserves attention before any use decision.

Melanoma case reports. Multiple published case reports describe melanoma diagnoses in Melanotan II users, often arising in pre-existing nevi that darkened or changed during use. The mechanism is plausible: MC1R activation in atypical melanocytes may stimulate proliferation, and existing dysplastic nevi may transform under sustained signaling. The literature includes a 2009 Lancet case report (Cardones and Grichnik) and later reports in dermatology journals through 2020.

Dysplastic nevi changes. Users frequently develop new pigmented lesions or report darkening and change in existing moles during Melanotan II cycles. Dermatology consensus is that anyone using Melanotan II should be monitored with regular skin examinations and that any changing nevus should be evaluated promptly.

Priapism. Multiple case reports of priapism requiring emergency intervention have been published. The MC4R activation mechanism that produces the sexual side effects can drive prolonged unwanted erections in male users. Some cases have required corporal aspiration.

Posterior reversible encephalopathy syndrome (PRES). A small number of case reports describe acute neurologic events including PRES in Melanotan II users. The mechanism may relate to acute blood pressure increase.

Renal infarction and rhabdomyolysis. Isolated case reports document serious vascular and muscular events. These are rare but documented.

Hyperpigmentation in non-cutaneous tissue. Buccal mucosa, lips, and ocular structures can develop pigmentation changes that may persist after discontinuation.

The combined adverse-event profile is substantively worse than for most peptides in current adult research settings. None of these is a theoretical concern. All are documented in published case reports.

Three related melanocortin agonists are sometimes conflated in online discussion.

Melanotan II. Non-selective melanocortin agonist. Activates MC1R, MC3R, MC4R, and MC5R. Produces tanning, sexual side effects, appetite suppression, and the documented adverse-event profile above. No regulatory approval anywhere.

PT-141 (bremelanotide, Vyleesi). Structurally derived from Melanotan II. Modified to maximize MC4R activity and minimize MC1R activity. Result: strong sexual arousal effects, minimal pigmentation. FDA-approved June 2019 for premenopausal women with hypoactive sexual desire disorder. The favorable comparison to Melanotan II reflects two decades of focused development to remove the most concerning effects of the parent compound.

Melanotan I (afamelanotide, Scenesse). A different melanocortin agonist developed by Clinuvel Pharmaceuticals. More selective for MC1R than Melanotan II. Received FDA approval in October 2019 for adults with erythropoietic protoporphyria. The Scenesse approval validated the medical use case for selective MC1R activation but does not apply to the cosmetic tanning use that Melanotan II is sold for.

For practical purposes: PT-141 is the FDA-approved option for sexual function (in women). Scenesse is the FDA-approved option for legitimate MC1R-related photosensitivity disorders. Melanotan II is the unregulated grey-market option with a substantial adverse-event burden and no approved indication anywhere.